• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.

作者信息

Kyle R A, Greipp P R, O'Fallon W M

出版信息

Blood. 1986 Jul;68(1):220-4.

PMID:3719098
Abstract

One hundred sixty-eight patients with primary systemic amyloidosis (AL) were identified. Median survival after diagnosis was 12 months and ranged from 4 months for patients presenting with congestive heart failure to 50 months for those presenting with peripheral neuropathy only. Utilizing the proportional-hazards model in a stepwise multivariate fashion to evaluate the simultaneous influence of putative risk factors as of diagnosis revealed that congestive heart failure, urine light chain, hepatomegaly, and multiple myeloma were the major factors adversely affecting survival during the first year after diagnosis. Serum creatinine, multiple myeloma, orthostatic hypotension, and monoclonal serum protein were the most important variables adversely affecting survival for patients surviving 1 year. These models were used to categorize patients according to the variables in the models into low-, moderate-, and high-risk groups for the first year after diagnosis and separately for subsequent years. The influence of these variables on survival is important in stratification of patients randomized to prospective clinical trials.

摘要

相似文献

1
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.
Blood. 1986 Jul;68(1):220-4.
2
Primary systemic amyloidosis--a diagnostic primer.原发性系统性淀粉样变性——诊断入门
Mayo Clin Proc. 1989 Dec;64(12):1505-19. doi: 10.1016/s0025-6196(12)65706-1.
3
Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients.
Am J Med. 1988 Jul;85(1):73-80. doi: 10.1016/0002-9343(88)90505-0.
4
Long-term survival (10 years or more) in 30 patients with primary amyloidosis.
Blood. 1999 Feb 1;93(3):1062-6.
5
Amyloidosis (AL). Clinical and laboratory features in 229 cases.淀粉样变性(AL型)。229例患者的临床及实验室特征。
Mayo Clin Proc. 1983 Oct;58(10):665-83.
6
Amyloidosis: review of 236 cases.淀粉样变性:236例病例回顾
Medicine (Baltimore). 1975 Jul;54(4):271-99. doi: 10.1097/00005792-197507000-00001.
7
Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.系统性淀粉样变性中的肾脏受累:一项关于生存和肾脏结局的意大利协作研究。
Nephrol Dial Transplant. 2008 Mar;23(3):941-51. doi: 10.1093/ndt/gfm684. Epub 2007 Oct 19.
8
Beta 2-microglobulin predicts survival in primary systemic amyloidosis.β2微球蛋白可预测原发性系统性淀粉样变性的生存期。
Am J Med. 1990 Nov;89(5):609-14. doi: 10.1016/0002-9343(90)90179-h.
9
Amyloidosis: prognosis and treatment.淀粉样变性:预后与治疗
Semin Arthritis Rheum. 1994 Oct;24(2):124-38. doi: 10.1016/s0049-0172(05)80006-x.
10
The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.浆细胞克隆性程度和骨髓浸润对AL淀粉样变性患者的预后产生不利影响。
Haematologica. 1999 Mar;84(3):218-21.

引用本文的文献

1
Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens.基于硼替佐米方案治疗的 AL 淀粉样变性患者游离轻链负荷的预测价值
Blood Adv. 2025 Aug 12;9(15):3771-3779. doi: 10.1182/bloodadvances.2024015528.
2
Echocardiographic findings of patients with transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样心肌病患者的超声心动图表现
J Echocardiogr. 2025 Mar;23(1):1-9. doi: 10.1007/s12574-024-00672-w. Epub 2024 Dec 27.
3
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis.
多域终点在轻链淀粉样变(AL)淀粉样变性中的开发和验证途径。
Ther Innov Regul Sci. 2024 Jul;58(4):600-609. doi: 10.1007/s43441-024-00641-6. Epub 2024 Apr 17.
4
A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis.采用右心房应变的新分期系统用于免疫球蛋白轻链心脏淀粉样变患者。
ESC Heart Fail. 2024 Jun;11(3):1612-1624. doi: 10.1002/ehf2.14710. Epub 2024 Feb 23.
5
Gastrointestinal Bleeding Caused by Large Intestine Amyloidosis.大肠淀粉样变性所致的胃肠道出血
Fed Pract. 2023 Aug;40(8):262-264. doi: 10.12788/fp.0389. Epub 2023 Aug 18.
6
Prognostic value of right ventricular global longitudinal strain in patients with immunoglobulin light-chain cardiac amyloidosis.免疫球蛋白轻链型心脏淀粉样变性患者右心室整体纵向应变的预后价值
Eur Heart J Open. 2023 May 9;3(3):oead048. doi: 10.1093/ehjopen/oead048. eCollection 2023 May.
7
Unusual Case of Nephrotic Syndrome From Light Chain Amyloidosis in a 37-Year-Old Patient.一名37岁患者因轻链淀粉样变性导致肾病综合征的罕见病例。
Cureus. 2021 Sep 20;13(9):e18120. doi: 10.7759/cureus.18120. eCollection 2021 Sep.
8
Biomarkers in AL Amyloidosis.AL 淀粉样变中的生物标志物。
Int J Mol Sci. 2021 Oct 9;22(20):10916. doi: 10.3390/ijms222010916.
9
Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach.免疫球蛋白轻链淀粉样变性:临床表现与诊断方法
J Adv Pract Oncol. 2019 Jul;10(5):470-481. doi: 10.6004/jadpro.2019.10.5.5. Epub 2019 Jul 1.
10
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.淀粉样变论坛:推进 AL 淀粉样变药物研发的公私合作伙伴关系。
Orphanet J Rare Dis. 2020 Sep 29;15(1):268. doi: 10.1186/s13023-020-01525-2.